NMC
ALXO icon

Nine Masts Capital’s ALX Oncology ALXO Stock Holding History

Nine Masts Capital’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.3K Buy
20,623
+5,148
+33% +$9.81K 0.01% 173
2025
Q4 		$17.5K Buy
+15,475
New +$23.4K ﹤0.01% 116

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Nine Masts Capital's ALXO Position: Q1 2026 in Review

Nine Masts Capital increased its ALX Oncology (ALXO) stake by 33% in Q1 2026, buying an estimated $9.81K and bringing the position to 20,623 shares worth $41.3K. The position accounts for 0.01% of the portfolio, ranked #173.

Nine Masts Capital first reported a position in ALXO in Q4 2025 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Nine Masts Capital held 20,623 shares of ALX Oncology worth $41.3K as of Q1 2026.
  • Nine Masts Capital bought 5,148 ALX Oncology shares in Q1 2026, an estimated $9.81K.
  • ALX Oncology made up 0.01% of Nine Masts Capital's portfolio in Q1 2026, its #173 holding.
  • Nine Masts Capital first reported a position in ALX Oncology in Q4 2025 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.